Therefore, FNDC5/irisin can act as an “exercise medicine” for cancer survivors undergoing thoracic RT who are not able to participate in an aerobic exercise rehabilitation program because of barriers experienced by cancer survivors, such as pain, fatigue, and environmental issues (Blaney et al., 2013; Romero et al., 2018). The gene discussed is FNDC5; the disease is cancer.